Nuvalent, Inc.
NUVLDelisted Jul 15, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001861560
Nuvalent, Inc. was delisted on Jul 15, 2026; its insiders filed their last Form 4 on Jul 17, 2026; 292 institutions reported holding it in 13F filings for Q2 2026, worth $9.29B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nuvalent, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 4 insiders, $8.23M in total
- Insiders trading
- 4
- Net value
- −$8.23M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nuvalent, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Deerfield Management Company, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 3 |
| Deerfield Mgmt L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Deerfield Partners, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Flynn James E | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 3 |
| Deerfield Healthcare Innovations Fund, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Deerfield Mgmt HIF, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Deerfield Private Design Fund IV, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Deerfield Mgmt IV, L.P. | Director, 10% Owner, Other: Director by Deputization | 0Indirect | Jul 17, 2026 | 2 |
| Meyers Michael L. | Director | 0 | Jul 15, 2026 | 2 |
| Balcom Alexandra | Chief Financial Officer | 0 | Jul 15, 2026 | 14 |
| Srivastava Sapna | Director | 0 | Jul 15, 2026 | 2 |
| Oliger Christy J. | Director | 0 | Jul 15, 2026 | 2 |
| Squarer Ron | Director | 0 | Jul 15, 2026 | 3 |
| Turner Christopher Durant | Chief Medical Officer | 0 | Jul 15, 2026 | 2 |
| Noci Darlene | Chief Development Officer | 0 | Jul 15, 2026 | 14 |
| Lane Benjamin | See Remarks | 0 | Jul 15, 2026 | 2 |
| Pelish Henry E. | Chief Scientific Officer | 0 | Jul 15, 2026 | 8 |
| Porter James Richard | President and CEO | 0 | Jul 15, 2026 | 9 |
| Miller Deborah Ann | Chief Legal Officer | 0 | Jul 15, 2026 | 12 |
| Protopapas Anna | Director | 0 | Jul 15, 2026 | 2 |
| Bogle Grant C. | Director | 0 | Jul 15, 2026 | 2 |
| Wheeler Cameron | Director | 0 | Jul 15, 2026 | 2 |
| Shair Matthew | Director | 201,672Indirect | Nov 26, 2025 | 2 |
| Pearlberg Joseph | Director | 5,146 | Jun 20, 2025 | 0 |
| Hack Andrew A. F. | Director | 1,447,267Indirect | Dec 13, 2024 | 0 |
| Conley Emily | Director | 2,507 | Aug 27, 2024 | 0 |
| Gilliland Dwight Gary | Director | 2,499 | Jun 14, 2024 | 0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | 897,671 | Aug 3, 2021 | 0 |
| Jackson Robert Bowers | Director | – | Jul 30, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)4:30 PM ET | Jul 9 | 1 day | Pelish Henry E.Chief Scientific Officer | SSaleClass A Common Stock | −2.11K | $123.81 | −$261.4K | −3.2%63.5K after | 10b5-1 |